ArticleFrontiers in endocrinology2025
Prevalence and risk factors of metabolic associated fatty liver disease in lean patients with bipolar disorder: a retrospective cross-sectional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) in lean individuals indicates metabolic dysfunction and elevates risks of metabolic and cardiovascular diseases. Thus far, no studies have specifically examined the prevalence and risk factors of MAFLD in lean individuals with bipolar disorder. Methods: This retrospective study included 1,072 patients aged 18 to 60 years. Participants were classified into two groups based on their Body Mass Index (BMI): those with a BMI ≥24 kg/m² were categorized as overweight or obese, while those with a BMI <24 kg/m² were defined as lean. Data were extracted from inpatient records at the Anhui Mental Health Center. Results: MAFLD prevalence markedly differed between groups (lean: 10.5% Conclusion: MAFLD is clinically relevant in lean BD patients. Fasting blood glucose level, triglyceride level, GGT level, female gender, and diabetes status were significant risk factors for MAFLD, whereas HDL level was a significant protective factor. Given the potential harm of MAFLD, it is essential to enhance vigilance and underscore the necessity of monitoring MAFLD among individuals with bipolar disorder, especially those who are lean.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.